Corporate Information – Page 3 – Alligator Bioscience

2025-05-20

Alligator Bioscience announces paediatric study waiver for mitazalimab granted by the European Medicines Agency

Lund, Sweden, 20 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical stage biotechnology company pioneering immuno-o ...

2025-05-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2025-05-15

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-05-12

Regulatory

Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...

2025-05-09

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-05-09

Lund, Sweden, 9 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the successful completion of the manufacture ...

2025-05-08

Regulatory

Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator’s new Board of ...

2025-05-07

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2025-04-282025-04-30

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...